Company
ASX:CHM
Chimeric Therapeutics Ltd, a clinical stage cell therapy company and an Australian leader in cell therapy, is focused on bringing the promise of cell therapy to life for more patients with cancer. The company's world class team of cell therapy pioneers is focused on the discovery, development, and commercialisation of today's most innovative solutions, and has shown a consistent ability to deliver on its objectives.
83 stories · page 4 of 5
“With its experience managing the complexity of cell therapy research programs and scientific support from the Moffitt Cancer Center, we believe that the team at OncoBay is uniquely positioned to support the expansion of the CHM 1101 (CLTX
The company is the only ASX-listed biotech conducting clinical trials in CAR-T technology and is focused on Phase 1 clinical trials for its CLTX-CAR T therapy for solid tumours.
“The team we’ve been able to assemble at Chimeric brings deep scientific and commercial cell therapy expertise to the business and gives us great confidence moving forward under Jenn’s leadership,” says chairman.
With this foundational IND, Chimeric will also further advance plans for a phase-I basket trial in solid tumours and a phase-II registration trial in Glioblastoma.
The company’s new advisory board will be made up of world-class experts who have been directly involved in the development of multiple cellular immunotherapies.
The board will be made up of world-class experts who have been directly involved in the successful development of multiple cellular immunotherapies.
Thanks to an exclusive licensing agreement with “a powerhouse in CAR T innovation”, Chimeric believes it is a step closer to bringing cell therapy to life for cancer patients.
The funds will support the company’s efforts to progress the development of CLTX CAR T and initiate the development of a cell therapy pipeline.
Dr Matcham brings to Chimeric a wealth of experience in the biopharma sector, following an instrumental three decades with cell therapy giant Celgene Corporation.
Dr Ren has nearly 20 years of experience developing and advancing cell therapy drug candidates from the preclinical stage through to commercial licensure.
The clinical-stage biotech company is looking at more curative therapies for patients with cancer, and not just therapies that delay disease progression.
The treatment of the first patient in the second dose cohort marks the introduction of dual routes of administration of CLTX CAR T cells with both ICT and ICV dosing.
During the quarter, Chimeric completed a $35 million initial public offering (IPO) and successfully listed on the ASX with support from new and existing institutional, professional and retail investors within Australia and overseas.
CHM has exclusive global rights to IP covering the Chlorotoxin CAR T which is in development for patients with recurrent glioblastoma and is also being investigated for development in patients with other solid tumours such as melanoma, smal
Chlorotoxin CAR T cell therapy is a first and potentially best in class therapy that has the potential to address the high unmet medical need of patients with recurrent/ progressive glioblastoma.
The biotech, which listed on the ASX on January 18, 2021, is developing its oncology pipeline with novel cell therapy technologies that will provide benefit to cancer patients globally.
The objectives of the study are to evaluate the safety and efficacy of CLTX CAR T for patients with recurrent or progressive glioblastoma.
The purchase of 24,800 shares at A$0.3178 per share on March 8 was the first by Cindy Elkins.
Dr Bourk will lead business and corporate development, with a near-term focus on Chimeric Therapeutics’ pipeline with additional novel cell therapies.
She has more than 30 years of experience in the biotech and high-tech industries, with roles at Juno Therapeutics, Genentech/Roche, and Ariba.
